Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734351 | 0.95 | LMNA (0.62) | LMNASLC1A3SLC1A2SLC1A1MGAM | |
| SCHEMBL4004096 | 0.93 | LMNA (0.66) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL11464663 | 0.89 | LMNA (0.61) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL1322681 | 0.87 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1MGAM | |
| SCHEMBL4962640 | 0.84 | LMNA (0.56) | LMNAMGAMGAASIMGAM2 | |
| SCHEMBL20954311 | 0.83 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1MGAM | |
| SCHEMBL7315668 | 0.83 | LMNA (0.70) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL10072208 | 0.82 | LMNA (0.53) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL13425332 | 0.81 | LMNA (0.58) | LMNASLC1A3SLC1A2SLC1A1MGAM | |
| SCHEMBL25381860 | 0.80 | LMNA (0.50) | LMNASLC1A3SLC1A2SLC1A1PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896452-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-7615635-B2 | N-formyl hydroxylamines | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | LEE KWANGHO | 2009-03-05 | — | — | US | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| EP-1896452-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis Pharma AG. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006127576-A2 | N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| US-4220795-A | MODIFIERS OF SMOOTH MUSCLE ACTIVITY, PLATELET ANTIAGGREGATING AGENTS, GASTRIC ANTISCRETORY AGENTS, BRONCHODILATORS | MILES LABORATORIES, INC. (US) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | PDF, MMP2, HNMT | LMNA 1847/4885SLC1A3 3131/4885SLC1A2 3161/4885 |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | PDF, HNMT, MMP2 | LMNA 2214/4885SLC1A3 2155/4885SLC1A2 2491/4885 |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | PDF, MMP2, PEPD | LMNA 2517/4885SLC1A3 2822/4885SLC1A2 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.